Method for enhancing pharmacokinetics using P450 inhibitors with piperidine carboxylate
Summary
USPTO granted Takeda Pharmaceutical patent US12594269B2 covering compositions comprising methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof combined with cytochrome P450 inhibitors to enhance pharmacokinetics and plasma concentration. The patent, containing 18 claims, is assigned to Takeda Pharmaceutical Company Limited with inventors including Mark Rogge, Hélène Faessel, Hong Lu, and others.
What changed
The USPTO issued patent grant US12594269B2 to Takeda Pharmaceutical Company Limited for a method of enhancing pharmacokinetics using cytochrome P450 inhibitors combined with a specific piperidine carboxylate compound. The patent covers compositions containing both the therapeutic compound and a metabolism-reducing agent, with 18 claims total.
For pharmaceutical companies and drug manufacturers, this patent establishes Takeda's IP rights in a pharmacokinetics enhancement technology that could affect R&D strategies, formulation approaches, and competitive positioning in related therapeutic areas. Companies developing similar compounds or methods should conduct freedom-to-operate analyses and consider potential licensing discussions.
What to do next
- Monitor for patent portfolio licensing opportunities
- Assess freedom-to-operate implications for related drug development programs
- Review for potential partnership or co-development arrangements
Archived snapshot
Apr 7, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450
Grant US12594269B2 Kind: B2 Apr 07, 2026
Assignee
Takeda Pharmaceutical Company Limited
Inventors
Mark Rogge, Hélène Faessel, Hong Lu, Karthik Venkatakrishnan, Liming Zhang, John Wagner
Abstract
Described herein are compositions comprising (a) methyl 3-((methyl sulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl) piperidine-1-carboxy late or a salt thereof; and (b) an agent for reducing metabolism of (a) and uses thereof.
CPC Classifications
A61K 31/445
Filing Date
2021-01-07
Application No.
17791302
Claims
18
Named provisions
Related changes
Get daily alerts for USPTO Patent Grants - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.